ArticleNature genetics2025
ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L.
Abstract read
In one paragraph
Article in Nature genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- ERG Orchestrates a Dedifferentiation-Senescence-Inflammation Triad in Prostate Cancer.Molecular cancer research : MCR · 2026Article
- Review
- Prostate Club-like Cells Reveal Context-Dependent Epithelial States in Homeostasis Remodeling and Cancer.Cells · 2026Review
- Integrated single-cell and spatial transcriptomic profiling decodes lineage plasticity and immune microenvironment remodeling in prostate cancer progression.Molecular cancer · 2026Article
- Non-Coding RNA Biomarkers in Prostate Cancer: Evidence Mapping and In Silico Characterization.Life (Basel, Switzerland) · 2026Article
- Single-cell and spatial omics of metabolic-immune ecosystems in prostate cancer: from androgen signaling to therapy resistance.Frontiers in immunology · 2026Review
- The Quartet of Core Oncogenic Drivers in Neuroendocrine Prostate Cancer: Multi-Omics Dataset Integration to Forge a Translational Link Between Biology and Precision Therapy.International journal of biological sciences · 2026Review
- ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L.Nature genetics · 2025Article
- Multi-Omics Meets Premalignancy: Paving the Way for Early Prevention of Cancer.Research (Washington, D.C.) · 2025Review
- The cell fates of intermediate cell population in prostate development.Cell insight · 2024Article
Corrections and comments
- Update of
Authors and funding
16 authors.
Weiran Feng *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. weiran.feng@fccc.edu.ORCID http://orcid.org/0000-0002-3422-4964
Erik Ladewig *Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matthew LangeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0009-0008-7526-2140
Nazifa SalsabeelHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Huiyong ZhaoAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Young Sun LeeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anuradha GopalanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hanzhi LuoMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wenfei KangMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ning FanMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eric RosiekMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-6355-1457
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-0171-3884
Brett S CarverHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5165-3544
Christina S LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-4571-5910
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. sawyersc@mskcc.org.ORCID http://orcid.org/0000-0003-4955-6475
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI David B. Solit · 2001 to 2026
$63.0MThe Center for Tumor-Immune Systems Biology at MSKCCU54CA274492 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI EMILY H CHENG · 2022 to 2026
$16.3MProject 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiationP01CA265768 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Massimo Loda · 2022 to 2026
$13.4MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CARVER, BRETT STEWART · 2017 to 2021
$6.8MWeill Cornell/Rockefeller/Sloan Kettering MST ProgramT32GM152349 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI KATHARINE C HSU · 2024 to 2026
$6.6MPatient-Derived Models of Prostate Cancer for Personalized MedicineU01CA224044 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, YU, FUTREAL, PHILLIP ANDREW · 2019 to 2023
$5.1MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MUnderstanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8MPSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapyR01CA257811 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CARVER, BRETT STEWART, GRIMM, JAN · 2021 to 2025
$3.6MUnderstanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistanceR01CA208100 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2017 to 2021
$2.5MUnderstanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.K08CA140946 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2009 to 2013
$796kNCI NIH HHS K08 CA140946NCI NIH HHS K99 CA276888NCI NIH HHS P01 CA265768NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R00 CA276888NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA208100NCI NIH HHS R01 CA257811NCI NIH HHS U01 CA224044NCI NIH HHS U54 CA224079NCI NIH HHS U54 CA274492NIDDK NIH HHS K99 DK128602NIDDK NIH HHS R00 DK128602NIGMS NIH HHS T32 GM152349Prostate Cancer Foundation (PCF) 20YOUN22U.S. Department of Defense (United States Department of Defense) W81XWH-19-1-0323U.S. Department of Defense (United States Department of Defense) W81XWH-21-1-0431U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) 1K99CA276888-01U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA008748U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA092629U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA155169U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA193837U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA224079U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA257811U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA274492U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) DK128602-03
Abstract
Despite the high prevalence of ERG transcription factor translocations in prostate cancer, the mechanism of tumorigenicity remains poorly understood. Using lineage tracing, we find the tumor-initiating activity of ERG resides in a subpopulation of murine basal cells that coexpress luminal genes (Basal
Indexed as
Histone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinProstatic NeoplasmsTranscriptional Regulator ERGAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMiceSingle-Cell AnalysisDOT1L protein, humanERG protein, humanHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinTranscriptional Regulator ERG
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.